Allopurinol
Myelodysplastic Syndrome With Excess Blasts-1
Masonic Cancer Center, University of MinnesotaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Myelodysplastic Syndrome With Excess Blasts-1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYCLOSPORIN A Singapore Eye Research Institute | Phase 4 | B |
METHOTREXATE Fred Hutchinson Cancer Center | Phase 2 | B |
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 2 | B |
Thiotepa Fred Hutchinson Cancer Center | Phase 2 | B |
Busulphan Fred Hutchinson Cancer Center | Phase 2 | B |
View all 13 →
Same molecule, other indications
Allopurinol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →